Trial · NCT03228394
Results by group390
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 390
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Placebo Cohort 1 | Day 3 post-infusion (60 hours post start of infusion) | -13.0 | Standard Deviation 10.10 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Ganaxolone Cohort 1 | Day 3 post-infusion (60 hours post start of infusion) | -12.0 | Standard Deviation 6.82 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Placebo Cohort 2 | Day 3 post-infusion (60 hours post start of infusion) | -14.0 | Standard Deviation 9.10 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Ganaxolone Cohort 2 | Day 3 post-infusion (60 hours post start of infusion) | -14.3 | Standard Deviation 10.23 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Placebo Cohort 3 | Day 3 post-infusion (60 hours post start of infusion) | -11.0 | Standard Deviation 6.58 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Ganaxolone Cohort 3 | Day 3 post-infusion (60 hours post start of infusion) | -11.3 | Standard Deviation 7.04 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Placebo Cohort 6 | Day 29 | -13.6 | Standard Deviation 11.51 | Scores on a scale |
| Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score | Ganaxolone Cohort 6 | Day 29 | -11.5 | Standard Deviation 11.43 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Placebo Cohort 6 | Day 1 post-infusion (6 hours post start of infusion) | -3.2 | Standard Deviation 6.85 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Ganaxolone Cohort 6 | Day 1 post-infusion (6 hours post start of infusion) | -6.1 | Standard Deviation 9.97 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Placebo Cohort 1 | Day 1 (12 hours post start of infusion) | -3.8 | Standard Deviation 7.18 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Ganaxolone Cohort 1 | Day 1 (12 hours post start of infusion) | -2.4 | Standard Deviation 1.52 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Placebo Cohort 2 | Day 1 (12 hours post start of infusion) | -3.2 | Standard Deviation 6.44 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Ganaxolone Cohort 2 | Day 1 (12 hours post start of infusion) | -2.7 | Standard Deviation 5.59 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Placebo Cohort 3 | Day 1 (12 hours post start of infusion) | -1.9 | Standard Deviation 4.20 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Ganaxolone Cohort 3 | Day 1 (12 hours post start of infusion) | 0.3 | Standard Deviation 2.92 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Placebo Cohort 1 | Day 2 (24 hours post start of infusion) | -8.0 | Standard Deviation 9.80 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Ganaxolone Cohort 1 | Day 2 (24 hours post start of infusion) | -3.8 | Standard Deviation 5.31 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Placebo Cohort 2 | Day 2 (24 hours post start of infusion) | -6.4 | Standard Deviation 7.33 | Scores on a scale |
| Change From Baseline in HAMD17 Total Score at Indicated Time Points | Ganaxolone Cohort 2 | Day 2 (24 hours post start of infusion) | -10.1 | Standard Deviation 8.90 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03228394/results